These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 33486611

  • 1. LncRNA UCA1 attenuated the killing effect of cytotoxic CD8 + T cells on anaplastic thyroid carcinoma via miR-148a/PD-L1 pathway.
    Wang X, Zhang Y, Zheng J, Yao C, Lu X.
    Cancer Immunol Immunother; 2021 Aug; 70(8):2235-2245. PubMed ID: 33486611
    [Abstract] [Full Text] [Related]

  • 2. LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195.
    Wang QM, Lian GY, Song Y, Huang YF, Gong Y.
    Life Sci; 2019 Aug 15; 231():116335. PubMed ID: 30898647
    [Abstract] [Full Text] [Related]

  • 3. PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer.
    Gray KD, McCloskey JE, Vedvyas Y, Kalloo OR, Eshaky SE, Yang Y, Shevlin E, Zaman M, Ullmann TM, Liang H, Stefanova D, Christos PJ, Scognamiglio T, Tassler AB, Zarnegar R, Fahey TJ, Jin MM, Min IM.
    Clin Cancer Res; 2020 Nov 15; 26(22):6003-6016. PubMed ID: 32887724
    [Abstract] [Full Text] [Related]

  • 4. Long noncoding RNA UCA1 promotes anaplastic thyroid cancer cell proliferation via miR‑135a‑mediated c‑myc activation.
    Wang Y, Hou Z, Li D.
    Mol Med Rep; 2018 Sep 15; 18(3):3068-3076. PubMed ID: 30015867
    [Abstract] [Full Text] [Related]

  • 5. miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression.
    Sheng W, Chen Y, Gong Y, Dong T, Zhang B, Gao W.
    Oncol Rep; 2016 Dec 15; 36(6):3387-3396. PubMed ID: 27779717
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer.
    Gunda V, Gigliotti B, Ndishabandi D, Ashry T, McCarthy M, Zhou Z, Amin S, Freeman GJ, Alessandrini A, Parangi S.
    Br J Cancer; 2018 Nov 15; 119(10):1223-1232. PubMed ID: 30327563
    [Abstract] [Full Text] [Related]

  • 9. FOXP4-AS1 promotes CD8+ T cell exhaustion and esophageal cancer immune escape through USP10-stabilized PD-L1.
    Shen GY, Zhang Y, Huang RZ, Huang ZY, Yang LY, Chen DZ, Yang SB.
    Immunol Res; 2024 Aug 15; 72(4):766-775. PubMed ID: 38687433
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Cancer-associated fibroblasts-derived exosomes promote lung cancer progression by OIP5-AS1/ miR-142-5p/ PD-L1 axis.
    Jiang Y, Wang K, Lu X, Wang Y, Chen J.
    Mol Immunol; 2021 Dec 15; 140():47-58. PubMed ID: 34653794
    [Abstract] [Full Text] [Related]

  • 14. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer.
    Brauner E, Gunda V, Vanden Borre P, Zurakowski D, Kim YS, Dennett KV, Amin S, Freeman GJ, Parangi S.
    Oncotarget; 2016 Mar 29; 7(13):17194-211. PubMed ID: 26943572
    [Abstract] [Full Text] [Related]

  • 15. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
    Bao L, Li Y, Hu X, Gong Y, Chen J, Huang P, Tan Z, Ge M, Pan Z.
    Int Immunopharmacol; 2024 May 30; 133():112102. PubMed ID: 38652971
    [Abstract] [Full Text] [Related]

  • 16. Tumor-Infiltrating T Cells and the PD-1 Checkpoint Pathway in Advanced Differentiated and Anaplastic Thyroid Cancer.
    Bastman JJ, Serracino HS, Zhu Y, Koenig MR, Mateescu V, Sams SB, Davies KD, Raeburn CD, McIntyre RC, Haugen BR, French JD.
    J Clin Endocrinol Metab; 2016 Jul 30; 101(7):2863-73. PubMed ID: 27045886
    [Abstract] [Full Text] [Related]

  • 17. LncRNA H19 Influences Cellular Activities via the miR-454-3p/BHLHE40 Axis in Anaplastic Thyroid Carcinoma.
    Wu Y, Yang J, Zhang H, Cheng J, Lei P, Huang J.
    Horm Metab Res; 2024 May 30; 56(5):392-399. PubMed ID: 38052232
    [Abstract] [Full Text] [Related]

  • 18. Knockdown of HCP5 exerts tumor-suppressive functions by up-regulating tumor suppressor miR-128-3p in anaplastic thyroid cancer.
    Chen J, Zhao D, Meng Q.
    Biomed Pharmacother; 2019 Aug 30; 116():108966. PubMed ID: 31102936
    [Abstract] [Full Text] [Related]

  • 19. N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer.
    Liu Z, Wang T, She Y, Wu K, Gu S, Li L, Dong C, Chen C, Zhou Y.
    Mol Cancer; 2021 Aug 20; 20(1):105. PubMed ID: 34416901
    [Abstract] [Full Text] [Related]

  • 20. Long noncoding RNA UCA1 regulates proliferation and apoptosis in multiple myeloma by targeting miR-331-3p/IL6R axis for the activation of JAK2/STAT3 pathway.
    Li JL, Liu XL, Guo SF, Yang Y, Zhu YL, Li JZ.
    Eur Rev Med Pharmacol Sci; 2019 Nov 20; 23(21):9238-9250. PubMed ID: 31773675
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.